
Global Chimeric Antigen Receptor Cell Therapy Market Research Report 2025(Status and Outlook)
Description
Report Overview
Chimeric Antigen Receptor (CAR) cell therapy is a revolutionary form of immunotherapy that involves genetically engineering a patient's T-cells to express CARs, which are synthetic receptors designed to recognize and bind to specific antigens on cancer cells, thereby triggering an immune response to destroy the malignant cells. This highly personalized treatment has shown remarkable success in treating certain hematologic malignancies, such as B-cell leukemias and lymphomas, with FDA-approved therapies like Kymriah and Yescarta demonstrating significant clinical efficacy. The market for CAR-T therapy is rapidly expanding due to increasing cancer prevalence, advancements in genetic engineering, and growing investment in biopharmaceutical R&D, though challenges such as high production costs, complex manufacturing processes, and severe side effects like cytokine release syndrome (CRS) limit broader adoption. Key players like Novartis, Gilead Sciences, and Bristol-Myers Squibb dominate the space, while emerging competitors focus on improving safety, scalability, and efficacy in solid tumors—a largely untapped market segment. Regulatory support and reimbursement frameworks are evolving to accommodate these high-cost therapies, with North America leading in adoption and Asia-Pacific showing accelerated growth due to rising healthcare investments and clinical trial activity. Future growth hinges on overcoming manufacturing bottlenecks, reducing costs, and expanding applications beyond hematologic cancers.
The global Chimeric Antigen Receptor Cell Therapy market size was estimated at USD 2214.71 million in 2024, exhibiting a CAGR of 25.80% during the forecast period.
This report provides a deep insight into the global Chimeric Antigen Receptor Cell Therapy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Chimeric Antigen Receptor Cell Therapy Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Chimeric Antigen Receptor Cell Therapy market in any manner.
Global Chimeric Antigen Receptor Cell Therapy Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Amgen Inc
Autolus Therapeutics Plc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
Bristol-Myers Squibb Co
bluebird bio Inc
CARsgen Therapeutics Ltd
Celgene Corp
Cell Medica Ltd
Cellular Biomedicine Group Inc
Celularity Inc
Celyad SA
Daiichi Sankyo Co Ltd
Fosun Pharmaceutical AG
Gilead Sciences Inc
Guangzhou Anjie Biomedical Technology Co Ltd
Hangzhou Converd Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HRAIN Biotechnology Co Ltd
Juno Therapeutics Inc
Kite Pharma Inc
Nanjing Legend Biotech Co Ltd
NantKwest Inc
Nkarta Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Sorrento Therapeutics Inc
Takara Bio Inc
Market Segmentation (by Type)
MonOthersapy
Combination Therapy
Market Segmentation (by Application)
Acute Leukemia
Non-hodgkin's Lymphoma
Multiple Myeloma
Transplant Rejection
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Chimeric Antigen Receptor Cell Therapy Market
Overview of the regional outlook of the Chimeric Antigen Receptor Cell Therapy Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Chimeric Antigen Receptor Cell Therapy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Chimeric Antigen Receptor Cell Therapy, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
Chimeric Antigen Receptor (CAR) cell therapy is a revolutionary form of immunotherapy that involves genetically engineering a patient's T-cells to express CARs, which are synthetic receptors designed to recognize and bind to specific antigens on cancer cells, thereby triggering an immune response to destroy the malignant cells. This highly personalized treatment has shown remarkable success in treating certain hematologic malignancies, such as B-cell leukemias and lymphomas, with FDA-approved therapies like Kymriah and Yescarta demonstrating significant clinical efficacy. The market for CAR-T therapy is rapidly expanding due to increasing cancer prevalence, advancements in genetic engineering, and growing investment in biopharmaceutical R&D, though challenges such as high production costs, complex manufacturing processes, and severe side effects like cytokine release syndrome (CRS) limit broader adoption. Key players like Novartis, Gilead Sciences, and Bristol-Myers Squibb dominate the space, while emerging competitors focus on improving safety, scalability, and efficacy in solid tumors—a largely untapped market segment. Regulatory support and reimbursement frameworks are evolving to accommodate these high-cost therapies, with North America leading in adoption and Asia-Pacific showing accelerated growth due to rising healthcare investments and clinical trial activity. Future growth hinges on overcoming manufacturing bottlenecks, reducing costs, and expanding applications beyond hematologic cancers.
The global Chimeric Antigen Receptor Cell Therapy market size was estimated at USD 2214.71 million in 2024, exhibiting a CAGR of 25.80% during the forecast period.
This report provides a deep insight into the global Chimeric Antigen Receptor Cell Therapy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Chimeric Antigen Receptor Cell Therapy Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Chimeric Antigen Receptor Cell Therapy market in any manner.
Global Chimeric Antigen Receptor Cell Therapy Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Amgen Inc
Autolus Therapeutics Plc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
Bristol-Myers Squibb Co
bluebird bio Inc
CARsgen Therapeutics Ltd
Celgene Corp
Cell Medica Ltd
Cellular Biomedicine Group Inc
Celularity Inc
Celyad SA
Daiichi Sankyo Co Ltd
Fosun Pharmaceutical AG
Gilead Sciences Inc
Guangzhou Anjie Biomedical Technology Co Ltd
Hangzhou Converd Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HRAIN Biotechnology Co Ltd
Juno Therapeutics Inc
Kite Pharma Inc
Nanjing Legend Biotech Co Ltd
NantKwest Inc
Nkarta Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Sorrento Therapeutics Inc
Takara Bio Inc
Market Segmentation (by Type)
MonOthersapy
Combination Therapy
Market Segmentation (by Application)
Acute Leukemia
Non-hodgkin's Lymphoma
Multiple Myeloma
Transplant Rejection
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Chimeric Antigen Receptor Cell Therapy Market
Overview of the regional outlook of the Chimeric Antigen Receptor Cell Therapy Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Chimeric Antigen Receptor Cell Therapy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Chimeric Antigen Receptor Cell Therapy, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
Table of Contents
204 Pages
- 1 Research Methodology and Statistical Scope
- 1.1 Market Definition and Statistical Scope of Chimeric Antigen Receptor Cell Therapy
- 1.2 Key Market Segments
- 1.2.1 Chimeric Antigen Receptor Cell Therapy Segment by Type
- 1.2.2 Chimeric Antigen Receptor Cell Therapy Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats
- 2 Chimeric Antigen Receptor Cell Therapy Market Overview
- 2.1 Global Market Overview
- 2.1.1 Global Chimeric Antigen Receptor Cell Therapy Market Size (M USD) Estimates and Forecasts (2020-2033)
- 2.1.2 Global Chimeric Antigen Receptor Cell Therapy Sales Estimates and Forecasts (2020-2033)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region
- 3 Chimeric Antigen Receptor Cell Therapy Market Competitive Landscape
- 3.1 Company Assessment Quadrant
- 3.2 Global Chimeric Antigen Receptor Cell Therapy Product Life Cycle
- 3.3 Global Chimeric Antigen Receptor Cell Therapy Sales by Manufacturers (2020-2025)
- 3.4 Global Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Manufacturers (2020-2025)
- 3.5 Chimeric Antigen Receptor Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.6 Global Chimeric Antigen Receptor Cell Therapy Average Price by Manufacturers (2020-2025)
- 3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
- 3.8 Chimeric Antigen Receptor Cell Therapy Market Competitive Situation and Trends
- 3.8.1 Chimeric Antigen Receptor Cell Therapy Market Concentration Rate
- 3.8.2 Global 5 and 10 Largest Chimeric Antigen Receptor Cell Therapy Players Market Share by Revenue
- 3.8.3 Mergers & Acquisitions, Expansion
- 4 Chimeric Antigen Receptor Cell Therapy Industry Chain Analysis
- 4.1 Chimeric Antigen Receptor Cell Therapy Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of Chimeric Antigen Receptor Cell Therapy Market
- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
- 5.4.1 New Product Developments
- 5.4.2 Mergers & Acquisitions
- 5.4.3 Expansions
- 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
- 5.5.1 Industry Policies Analysis
- 5.5.2 Economic Environment Analysis
- 5.5.3 Social Environment Analysis
- 5.5.4 Technological Environment Analysis
- 5.6 Global Chimeric Antigen Receptor Cell Therapy Market Porter's Five Forces Analysis
- 5.6.1 Global Trade Frictions
- 5.6.2 U.S. Tariff Policy – April 2025
- 5.6.3 Global Trade Frictions and Their Impacts to Chimeric Antigen Receptor Cell Therapy Market
- 5.7 ESG Ratings of Leading Companies
- 6 Chimeric Antigen Receptor Cell Therapy Market Segmentation by Type
- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Chimeric Antigen Receptor Cell Therapy Sales Market Share by Type (2020-2025)
- 6.3 Global Chimeric Antigen Receptor Cell Therapy Market Size Market Share by Type (2020-2025)
- 6.4 Global Chimeric Antigen Receptor Cell Therapy Price by Type (2020-2025)
- 7 Chimeric Antigen Receptor Cell Therapy Market Segmentation by Application
- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Chimeric Antigen Receptor Cell Therapy Market Sales by Application (2020-2025)
- 7.3 Global Chimeric Antigen Receptor Cell Therapy Market Size (M USD) by Application (2020-2025)
- 7.4 Global Chimeric Antigen Receptor Cell Therapy Sales Growth Rate by Application (2020-2025)
- 8 Chimeric Antigen Receptor Cell Therapy Market Sales by Region
- 8.1 Global Chimeric Antigen Receptor Cell Therapy Sales by Region
- 8.1.1 Global Chimeric Antigen Receptor Cell Therapy Sales by Region
- 8.1.2 Global Chimeric Antigen Receptor Cell Therapy Sales Market Share by Region
- 8.2 Global Chimeric Antigen Receptor Cell Therapy Market Size by Region
- 8.2.1 Global Chimeric Antigen Receptor Cell Therapy Market Size by Region
- 8.2.2 Global Chimeric Antigen Receptor Cell Therapy Market Size Market Share by Region
- 8.3 North America
- 8.3.1 North America Chimeric Antigen Receptor Cell Therapy Sales by Country
- 8.3.2 North America Chimeric Antigen Receptor Cell Therapy Market Size by Country
- 8.3.3 U.S. Market Overview
- 8.3.4 Canada Market Overview
- 8.3.5 Mexico Market Overview
- 8.4 Europe
- 8.4.1 Europe Chimeric Antigen Receptor Cell Therapy Sales by Country
- 8.4.2 Europe Chimeric Antigen Receptor Cell Therapy Market Size by Country
- 8.4.3 Germany Market Overview
- 8.4.4 France Market Overview
- 8.4.5 U.K. Market Overview
- 8.4.6 Italy Market Overview
- 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
- 8.5.1 Asia Pacific Chimeric Antigen Receptor Cell Therapy Sales by Region
- 8.5.2 Asia Pacific Chimeric Antigen Receptor Cell Therapy Market Size by Region
- 8.5.3 China Market Overview
- 8.5.4 Japan Market Overview
- 8.5.5 South Korea Market Overview
- 8.5.6 India Market Overview
- 8.5.7 Southeast Asia Market Overview
- 8.6 South America
- 8.6.1 South America Chimeric Antigen Receptor Cell Therapy Sales by Country
- 8.6.2 South America Chimeric Antigen Receptor Cell Therapy Market Size by Country
- 8.6.3 Brazil Market Overview
- 8.6.4 Argentina Market Overview
- 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
- 8.7.1 Middle East and Africa Chimeric Antigen Receptor Cell Therapy Sales by Region
- 8.7.2 Middle East and Africa Chimeric Antigen Receptor Cell Therapy Market Size by Region
- 8.7.3 Saudi Arabia Market Overview
- 8.7.4 UAE Market Overview
- 8.7.5 Egypt Market Overview
- 8.7.6 Nigeria Market Overview
- 8.7.7 South Africa Market Overview
- 9 Chimeric Antigen Receptor Cell Therapy Market Production by Region
- 9.1 Global Production of Chimeric Antigen Receptor Cell Therapy by Region(2020-2025)
- 9.2 Global Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Region (2020-2025)
- 9.3 Global Chimeric Antigen Receptor Cell Therapy Production, Revenue, Price and Gross Margin (2020-2025)
- 9.4 North America Chimeric Antigen Receptor Cell Therapy Production
- 9.4.1 North America Chimeric Antigen Receptor Cell Therapy Production Growth Rate (2020-2025)
- 9.4.2 North America Chimeric Antigen Receptor Cell Therapy Production, Revenue, Price and Gross Margin (2020-2025)
- 9.5 Europe Chimeric Antigen Receptor Cell Therapy Production
- 9.5.1 Europe Chimeric Antigen Receptor Cell Therapy Production Growth Rate (2020-2025)
- 9.5.2 Europe Chimeric Antigen Receptor Cell Therapy Production, Revenue, Price and Gross Margin (2020-2025)
- 9.6 Japan Chimeric Antigen Receptor Cell Therapy Production (2020-2025)
- 9.6.1 Japan Chimeric Antigen Receptor Cell Therapy Production Growth Rate (2020-2025)
- 9.6.2 Japan Chimeric Antigen Receptor Cell Therapy Production, Revenue, Price and Gross Margin (2020-2025)
- 9.7 China Chimeric Antigen Receptor Cell Therapy Production (2020-2025)
- 9.7.1 China Chimeric Antigen Receptor Cell Therapy Production Growth Rate (2020-2025)
- 9.7.2 China Chimeric Antigen Receptor Cell Therapy Production, Revenue, Price and Gross Margin (2020-2025)
- 10 Key Companies Profile
- 10.1 Amgen Inc
- 10.1.1 Amgen Inc Basic Information
- 10.1.2 Amgen Inc Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.1.3 Amgen Inc Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.1.4 Amgen Inc Business Overview
- 10.1.5 Amgen Inc SWOT Analysis
- 10.1.6 Amgen Inc Recent Developments
- 10.2 Autolus Therapeutics Plc
- 10.2.1 Autolus Therapeutics Plc Basic Information
- 10.2.2 Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.2.3 Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.2.4 Autolus Therapeutics Plc Business Overview
- 10.2.5 Autolus Therapeutics Plc SWOT Analysis
- 10.2.6 Autolus Therapeutics Plc Recent Developments
- 10.3 Beijing Immunochina Medical Science and Technology Co Ltd
- 10.3.1 Beijing Immunochina Medical Science and Technology Co Ltd Basic Information
- 10.3.2 Beijing Immunochina Medical Science and Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.3.3 Beijing Immunochina Medical Science and Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.3.4 Beijing Immunochina Medical Science and Technology Co Ltd Business Overview
- 10.3.5 Beijing Immunochina Medical Science and Technology Co Ltd SWOT Analysis
- 10.3.6 Beijing Immunochina Medical Science and Technology Co Ltd Recent Developments
- 10.4 Bellicum Pharmaceuticals Inc
- 10.4.1 Bellicum Pharmaceuticals Inc Basic Information
- 10.4.2 Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.4.3 Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.4.4 Bellicum Pharmaceuticals Inc Business Overview
- 10.4.5 Bellicum Pharmaceuticals Inc Recent Developments
- 10.5 Bristol-Myers Squibb Co
- 10.5.1 Bristol-Myers Squibb Co Basic Information
- 10.5.2 Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.5.3 Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.5.4 Bristol-Myers Squibb Co Business Overview
- 10.5.5 Bristol-Myers Squibb Co Recent Developments
- 10.6 bluebird bio Inc
- 10.6.1 bluebird bio Inc Basic Information
- 10.6.2 bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.6.3 bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.6.4 bluebird bio Inc Business Overview
- 10.6.5 bluebird bio Inc Recent Developments
- 10.7 CARsgen Therapeutics Ltd
- 10.7.1 CARsgen Therapeutics Ltd Basic Information
- 10.7.2 CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.7.3 CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.7.4 CARsgen Therapeutics Ltd Business Overview
- 10.7.5 CARsgen Therapeutics Ltd Recent Developments
- 10.8 Celgene Corp
- 10.8.1 Celgene Corp Basic Information
- 10.8.2 Celgene Corp Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.8.3 Celgene Corp Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.8.4 Celgene Corp Business Overview
- 10.8.5 Celgene Corp Recent Developments
- 10.9 Cell Medica Ltd
- 10.9.1 Cell Medica Ltd Basic Information
- 10.9.2 Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.9.3 Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.9.4 Cell Medica Ltd Business Overview
- 10.9.5 Cell Medica Ltd Recent Developments
- 10.10 Cellular Biomedicine Group Inc
- 10.10.1 Cellular Biomedicine Group Inc Basic Information
- 10.10.2 Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.10.3 Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.10.4 Cellular Biomedicine Group Inc Business Overview
- 10.10.5 Cellular Biomedicine Group Inc Recent Developments
- 10.11 Celularity Inc
- 10.11.1 Celularity Inc Basic Information
- 10.11.2 Celularity Inc Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.11.3 Celularity Inc Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.11.4 Celularity Inc Business Overview
- 10.11.5 Celularity Inc Recent Developments
- 10.12 Celyad SA
- 10.12.1 Celyad SA Basic Information
- 10.12.2 Celyad SA Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.12.3 Celyad SA Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.12.4 Celyad SA Business Overview
- 10.12.5 Celyad SA Recent Developments
- 10.13 Daiichi Sankyo Co Ltd
- 10.13.1 Daiichi Sankyo Co Ltd Basic Information
- 10.13.2 Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.13.3 Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.13.4 Daiichi Sankyo Co Ltd Business Overview
- 10.13.5 Daiichi Sankyo Co Ltd Recent Developments
- 10.14 Fosun Pharmaceutical AG
- 10.14.1 Fosun Pharmaceutical AG Basic Information
- 10.14.2 Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.14.3 Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.14.4 Fosun Pharmaceutical AG Business Overview
- 10.14.5 Fosun Pharmaceutical AG Recent Developments
- 10.15 Gilead Sciences Inc
- 10.15.1 Gilead Sciences Inc Basic Information
- 10.15.2 Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.15.3 Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.15.4 Gilead Sciences Inc Business Overview
- 10.15.5 Gilead Sciences Inc Recent Developments
- 10.16 Guangzhou Anjie Biomedical Technology Co Ltd
- 10.16.1 Guangzhou Anjie Biomedical Technology Co Ltd Basic Information
- 10.16.2 Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.16.3 Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.16.4 Guangzhou Anjie Biomedical Technology Co Ltd Business Overview
- 10.16.5 Guangzhou Anjie Biomedical Technology Co Ltd Recent Developments
- 10.17 Hangzhou Converd Co Ltd
- 10.17.1 Hangzhou Converd Co Ltd Basic Information
- 10.17.2 Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.17.3 Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.17.4 Hangzhou Converd Co Ltd Business Overview
- 10.17.5 Hangzhou Converd Co Ltd Recent Developments
- 10.18 Hebei Senlang Biotechnology Inc Ltd
- 10.18.1 Hebei Senlang Biotechnology Inc Ltd Basic Information
- 10.18.2 Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.18.3 Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.18.4 Hebei Senlang Biotechnology Inc Ltd Business Overview
- 10.18.5 Hebei Senlang Biotechnology Inc Ltd Recent Developments
- 10.19 HRAIN Biotechnology Co Ltd
- 10.19.1 HRAIN Biotechnology Co Ltd Basic Information
- 10.19.2 HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.19.3 HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.19.4 HRAIN Biotechnology Co Ltd Business Overview
- 10.19.5 HRAIN Biotechnology Co Ltd Recent Developments
- 10.20 Juno Therapeutics Inc
- 10.20.1 Juno Therapeutics Inc Basic Information
- 10.20.2 Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.20.3 Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.20.4 Juno Therapeutics Inc Business Overview
- 10.20.5 Juno Therapeutics Inc Recent Developments
- 10.21 Kite Pharma Inc
- 10.21.1 Kite Pharma Inc Basic Information
- 10.21.2 Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.21.3 Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.21.4 Kite Pharma Inc Business Overview
- 10.21.5 Kite Pharma Inc Recent Developments
- 10.22 Nanjing Legend Biotech Co Ltd
- 10.22.1 Nanjing Legend Biotech Co Ltd Basic Information
- 10.22.2 Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.22.3 Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.22.4 Nanjing Legend Biotech Co Ltd Business Overview
- 10.22.5 Nanjing Legend Biotech Co Ltd Recent Developments
- 10.23 NantKwest Inc
- 10.23.1 NantKwest Inc Basic Information
- 10.23.2 NantKwest Inc Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.23.3 NantKwest Inc Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.23.4 NantKwest Inc Business Overview
- 10.23.5 NantKwest Inc Recent Developments
- 10.24 Nkarta Inc
- 10.24.1 Nkarta Inc Basic Information
- 10.24.2 Nkarta Inc Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.24.3 Nkarta Inc Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.24.4 Nkarta Inc Business Overview
- 10.24.5 Nkarta Inc Recent Developments
- 10.25 Novartis AG
- 10.25.1 Novartis AG Basic Information
- 10.25.2 Novartis AG Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.25.3 Novartis AG Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.25.4 Novartis AG Business Overview
- 10.25.5 Novartis AG Recent Developments
- 10.26 Ono Pharmaceutical Co Ltd
- 10.26.1 Ono Pharmaceutical Co Ltd Basic Information
- 10.26.2 Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.26.3 Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.26.4 Ono Pharmaceutical Co Ltd Business Overview
- 10.26.5 Ono Pharmaceutical Co Ltd Recent Developments
- 10.27 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
- 10.27.1 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Basic Information
- 10.27.2 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.27.3 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.27.4 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Business Overview
- 10.27.5 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Recent Developments
- 10.28 Sorrento Therapeutics Inc
- 10.28.1 Sorrento Therapeutics Inc Basic Information
- 10.28.2 Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.28.3 Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.28.4 Sorrento Therapeutics Inc Business Overview
- 10.28.5 Sorrento Therapeutics Inc Recent Developments
- 10.29 Takara Bio Inc
- 10.29.1 Takara Bio Inc Basic Information
- 10.29.2 Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Product Overview
- 10.29.3 Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Product Market Performance
- 10.29.4 Takara Bio Inc Business Overview
- 10.29.5 Takara Bio Inc Recent Developments
- 11 Chimeric Antigen Receptor Cell Therapy Market Forecast by Region
- 11.1 Global Chimeric Antigen Receptor Cell Therapy Market Size Forecast
- 11.2 Global Chimeric Antigen Receptor Cell Therapy Market Forecast by Region
- 11.2.1 North America Market Size Forecast by Country
- 11.2.2 Europe Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Country
- 11.2.3 Asia Pacific Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Region
- 11.2.4 South America Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Country
- 11.2.5 Middle East and Africa Forecasted Sales of Chimeric Antigen Receptor Cell Therapy by Country
- 12 Forecast Market by Type and by Application (2026-2033)
- 12.1 Global Chimeric Antigen Receptor Cell Therapy Market Forecast by Type (2026-2033)
- 12.1.1 Global Forecasted Sales of Chimeric Antigen Receptor Cell Therapy by Type (2026-2033)
- 12.1.2 Global Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Type (2026-2033)
- 12.1.3 Global Forecasted Price of Chimeric Antigen Receptor Cell Therapy by Type (2026-2033)
- 12.2 Global Chimeric Antigen Receptor Cell Therapy Market Forecast by Application (2026-2033)
- 12.2.1 Global Chimeric Antigen Receptor Cell Therapy Sales (K MT) Forecast by Application
- 12.2.2 Global Chimeric Antigen Receptor Cell Therapy Market Size (M USD) Forecast by Application (2026-2033)
- 13 Conclusion and Key Findings
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.